Sintilimab Clinical Trials
69 recruitingDrug
Phase 249Phase 110Phase 39Not Applicable4
Showing 1–20 of 69 trials
Recruiting
Phase 2
A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer
BRAF V600E
Tianjin Medical University Cancer Institute and Hospital49 enrolled4 locationsNCT07506109
Recruiting
Phase 1
Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours
ImmVirx Pty Ltd70 enrolled3 locationsNCT05427487
Recruiting
Phase 1
GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Study
West China Hospital9 enrolled1 locationNCT07457281
Recruiting
Phase 2
A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma
Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Fudan University276 enrolled1 locationNCT07492615
Recruiting
Phase 3
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
Chipscreen Biosciences, Ltd.430 enrolled1 locationNCT06497985
Recruiting
Phase 2
Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.
The First Affiliated Hospital with Nanjing Medical University39 enrolled1 locationNCT07394387
Recruiting
Phase 3
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
Nasopharyngeal Carcinoma (NPC)
First Affiliated Hospital of Guangxi Medical University266 enrolled1 locationNCT07459296
Recruiting
Not Applicable
SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC
Rectal Cancer, Adenocarcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology49 enrolled1 locationNCT07474103
Recruiting
Phase 2
Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma
Colon Adenocarcinoma
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University106 enrolled1 locationNCT07468630
Recruiting
Phase 2
Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery
Mucosal MelanomaPD-L1 Positive
The First Hospital of Jilin University220 enrolled1 locationNCT07400302
Recruiting
Phase 2
Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
MRDNSCLC (Non-small Cell Lung Cancer)II-IIIB Stages+1 more
Guangdong Association of Clinical Trials115 enrolled2 locationsNCT07120698
Recruiting
Phase 2
Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer
Lung Squamous Cell Carcinoma
Sichuan University114 enrolled6 locationsNCT06121505
Recruiting
Phase 2
Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma
MetastaticAppendix CarcinomaAdenocarcinoma of Small Intestine
Sun Yat-sen University36 enrolled1 locationNCT05472948
Recruiting
Phase 2
A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer
Gastric Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University460 enrolled1 locationNCT07263386
Recruiting
Phase 2
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
HCC - Hepatocellular Carcinoma
Peking Union Medical College Hospital300 enrolled1 locationNCT07157969
Recruiting
Phase 2
Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer
Gastric Cancer
Fudan University30 enrolled1 locationNCT07194005
Recruiting
Phase 3
Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC
Radiotherapy, AdjuvantHepatocellular Carcinoma (HCC)Immune Checkpoint Inhibitor+2 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences286 enrolled1 locationNCT07186621
Recruiting
Not Applicable
A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer
Jinzhou Medical University80 enrolled1 locationNCT06512207
Recruiting
Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma
Advanced Hepatocellular CarcinomaBevacizumabAnti-PD1/PDL1 Antibody
Sun Yat-sen University240 enrolled1 locationNCT06323382
Recruiting
Phase 2
Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma
Primary Central Nervous System Hodgkin Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University19 enrolled1 locationNCT04961515